This phase III trial is trying to understand whether adding a form of targeted therapy to standard chemotherapy will improve overall survival for patients with malignant pleural mesothelioma.
This trial is treating patients with malignant pleural mesothelioma.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Australasian Lung Cancer Trials Group (ALTG)
Other Non-Commercial Sponsor
University of Sydney
Two thirds of eligible patients will be randomly assigned to receive durvalumab in addition to standard chemotherapy containing pemetrexed and cisplatin. One third of eligible patients will receive chemotherapy alone, followed by observation.
Recruiting Hospitals Read More